PYC Therapeutics Limited (ASX:PYC)
Australia
· Delayed Price · Currency is AUD 1.485
-0.015 (-1.00%)
At close: Dec 5, 2025
PYC Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| Other Revenue | 23.49 | 22.06 | 15.81 | 16.04 | 3.07 | Upgrade
|
| Revenue | 23.49 | 22.06 | 15.81 | 16.04 | 3.07 | Upgrade
|
| Revenue Growth (YoY) | 6.50% | 39.56% | -1.47% | 421.83% | 28.33% | Upgrade
|
| Gross Profit | 23.49 | 22.06 | 15.81 | 16.04 | 3.07 | Upgrade
|
| Selling, General & Admin | 7.07 | 4.51 | 4.09 | 6.3 | 7.83 | Upgrade
|
| Research & Development | 70.05 | 56.41 | 35.15 | 24.03 | 14 | Upgrade
|
| Operating Expenses | 77.12 | 60.92 | 39.24 | 30.33 | 21.83 | Upgrade
|
| Operating Income | -53.63 | -38.86 | -23.43 | -14.29 | -18.76 | Upgrade
|
| Interest Expense | -0.06 | -0.05 | -0.03 | -0.03 | -0.04 | Upgrade
|
| Interest & Investment Income | 2.68 | 0.8 | 0.08 | 0.02 | 0.11 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | -51.01 | -38.11 | -23.38 | -14.29 | -18.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.02 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.06 | Upgrade
|
| Pretax Income | -51.01 | -38.11 | -23.36 | -14.29 | -18.63 | Upgrade
|
| Earnings From Continuing Operations | -51.01 | -38.11 | -23.36 | -14.29 | -18.63 | Upgrade
|
| Minority Interest in Earnings | 0.71 | 0.39 | 0.57 | 0.43 | 0.86 | Upgrade
|
| Net Income | -50.3 | -37.73 | -22.79 | -13.86 | -17.77 | Upgrade
|
| Net Income to Common | -50.3 | -37.73 | -22.79 | -13.86 | -17.77 | Upgrade
|
| Shares Outstanding (Basic) | 501 | 394 | 321 | 318 | 309 | Upgrade
|
| Shares Outstanding (Diluted) | 501 | 394 | 321 | 318 | 309 | Upgrade
|
| Shares Change (YoY) | 27.16% | 22.59% | 0.93% | 2.89% | 12.58% | Upgrade
|
| EPS (Basic) | -0.10 | -0.10 | -0.07 | -0.04 | -0.06 | Upgrade
|
| EPS (Diluted) | -0.10 | -0.10 | -0.07 | -0.04 | -0.06 | Upgrade
|
| Free Cash Flow | -52.54 | -38.9 | -24.91 | -22.17 | -12.38 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | -0.10 | -0.08 | -0.07 | -0.04 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -228.26% | -176.15% | -148.24% | -89.05% | -610.16% | Upgrade
|
| Profit Margin | -214.11% | -171.02% | -144.18% | -86.41% | -577.93% | Upgrade
|
| Free Cash Flow Margin | -223.61% | -176.32% | -157.61% | -138.19% | -402.76% | Upgrade
|
| EBITDA | -52.88 | -38.12 | -22.8 | -13.69 | -18.33 | Upgrade
|
| EBITDA Margin | -225.06% | -172.80% | -144.25% | -85.31% | - | Upgrade
|
| D&A For EBITDA | 0.75 | 0.74 | 0.63 | 0.6 | 0.42 | Upgrade
|
| EBIT | -53.63 | -38.86 | -23.43 | -14.29 | -18.76 | Upgrade
|
| EBIT Margin | -228.26% | -176.15% | -148.24% | -89.05% | - | Upgrade
|
| Revenue as Reported | 26.17 | 22.86 | 15.91 | 16.07 | 3.24 | Upgrade
|
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.